

1 **Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is**
2 **associated with faster viral clearance and COVID-19 symptom resolution.**

3 Nora Pisanic¹, Annukka A. R. Antar², Marissa K. Hetrich³, Zoe O. Demko², Xueyan Zhang³, Kristoffer
4 Spicer¹, Kate L. Kruczynski¹, Barbara Detrick⁴, William Clarke⁴, Maria Deloria Knoll³, David L. Thomas^{2,4},
5 Fatimah S. Dawood⁵, Vic Veguilla⁵, Ruth A. Karron³, Yukari C. Manabe^{2,3,7}, Christopher D. Heaney^{1,3,6}

6 **Affiliations**

7 ¹Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns
8 Hopkins University, Baltimore, Maryland, USA

9 ²Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University,
10 Baltimore, Maryland, USA

11 ³Department of International Health, Bloomberg School of Public Health, Johns Hopkins University,
12 Baltimore, Maryland, USA

13 ⁴Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

14 ⁵COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

15 ⁶Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore,
16 Maryland, USA

17 ⁷Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns
18 Hopkins University, Baltimore, Maryland, USA

19

20 **Corresponding author:** Christopher D. Heaney, Department of Environmental Health and Engineering,
21 Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., W7033B, Baltimore, MD USA, E-
22 mail: cheaney1@jhu.edu Phone: (443) 287-4989

23

24 **Keywords**

25 SARS-CoV-2, COVID-19, mucosal immunity, oral fluid, intranasal vaccines, multiplex, long COVID, PACS

26

27 **Disclaimer**

28 The findings and conclusions in this report are those of the authors and do not necessarily represent the
29 official position of the Centers for Disease Control and Prevention.

30

31 **Abstract**

32 High priority efforts are under way to support the development of novel mucosal COVID-19 vaccines,
33 such as the US Government's Project *NextGen* and the Center for Epidemic Preparedness Innovations'
34 (CEPI) goal to respond to the next pandemic with a new vaccine in 100 days. However, there is limited
35 consensus about the complementary role of mucosal immunity in disease progression and how the
36 immunogenicity of mucosal vaccines will be evaluated. This study investigated the role of oral mucosal
37 antibody responses in viral clearance and in COVID-19 symptom duration.

38 Participants with PCR-confirmed SARS-CoV-2 infection provided oral fluid for testing with SARS-CoV-2
39 antibody multiplex assays, nasal swabs for RT-PCR and symptom information at up to eight follow-ups
40 from April 2020 to February 2022.

41 High and moderate oral fluid anti-spike (S) SIgA post infection was associated with significantly higher
42 likelihood of viral clearance and of COVID-19 symptom resolution across age groups. Those with high
43 and moderate anti-S SIgA cleared the virus and recovered 14 days (95% CI: 10-18 days) and 9-10 days
44 (95% CI: 6-14 days) earlier, respectively. Delayed but higher oral fluid anti-S IgG was associated with
45 significantly longer time to viral clearance and recovery. The effect size of moderate or high SIgA was
46 equivalent to prior COVID-19 vaccine immunity, which was also associated with faster clearance and
47 recovery. Unvaccinated adults with prolonged COVID-19 symptoms had significantly lower anti-RBD SIgA
48 15-30 days after infection onset ($p < 0.001$).

49 Robust mucosal SIgA early post infection appears to support faster clearance of SARS-CoV-2 and
50 recovery from COVID-19 symptoms. This research underscores the importance of harmonizing mucosal
51 immune response assays to evaluate new vaccines that can boost local mucosal immunity.

52 **Introduction**

53 While COVID-19 vaccines have saved millions of lives in the US, they have not stopped SARS-CoV-2
54 breakthrough infections or transmission of ever evolving variants. Despite triple vaccination, multiple
55 studies have shown that breakthrough SARS-CoV-2 infections are common with the rapidly evolving
56 omicron variants.(1,2) Currently approved intramuscular COVID-19 vaccines elicit strong serum
57 neutralizing antibody (nAb) titers and binding IgG to SARS-CoV-2 spike protein (S), which have been
58 identified as correlates of protection from symptomatic and severe COVID-19, however, they confer
59 little mucosal immunity at the site of virus entry.(3) Blood nAb titers and anti-S IgG levels decline within
60 months, resulting in the need for multiple intramuscular boosters with updated composition to match
61 circulating variants. To break this continuing infection and transmission cycle, novel mucosal vaccines
62 are being developed with support of national and international programs, such as the US government's
63 Project NextGen and the Center for Epidemic Preparedness Innovations (CEPI) with the goal to respond
64 to the next pandemic with a new vaccine in 100 days.(4)

65 Mucosal SARS-CoV-2 anti-S IgA was observed to be a correlate for prevention of omicron infection as
66 determined by positive polymerase chain reaction (PCR) results for viral RNA in triple-vaccinated health
67 care workers. (5) Early in the COVID-19 pandemic, higher anti-RBD antibody levels in nasal mucosal lining
68 fluid were shown to be associated with lower viral loads after PCR-confirmed SARS-CoV-2 infection.(6)
69 Another recent study showed that time to mounting an anti-S secretory IgA response in the nasal cavity
70 correlated significantly with the duration of viral shedding determined by virus culture. However, in that
71 study, time to seroconversion and duration of viral shedding were both estimated from models based
72 on different study populations. (7) And less is known about the role of mucosal antibody responses in
73 oral fluid as a correlate of protection from other aspects of COVID-19 including time to viral clearance
74 (first PCR negative test after COVID-19 infection), time to symptom resolution, and risk of developing
75 Post COVID Conditions.(8) We sought to determine whether mucosal humoral antibody responses to
76 SARS-CoV-2 were associated with viral clearance and symptom resolution. A better understanding of the
77 role of mucosal immune responses will help inform intranasal COVID-19 vaccination strategies that
78 boost mucosal immunity moving forward and assay standardization and harmonization efforts to assess
79 immune responses in different mucosal compartments.(9,10)

80 **Methods**

81 Study design

82 This study assessed oral mucosal SARS-CoV-2 antibody responses in individuals with PCR-confirmed
83 SARS-CoV-2 infection who participated in one of two prospective cohort studies, OutSMART (11,12) or
84 SEARCh (13,14). The OutSMART study was approved by the Johns Hopkins University School of Medicine
85 Institutional Review Board (IRB; IRB00259948). The SEARCh study was approved by the IRB of Johns
86 Hopkins University Bloomberg School of Public Health (IRB00014200); the IRB of the Centers for Disease
87 Control and Prevention approved the study based on the review of the Johns Hopkins University
88 Bloomberg School of Public Health IRB.

89 Briefly, OutSMART enrolled predominantly adult participants who were identified through the Johns
90 Hopkins Outpatient SARS-CoV-2 testing network and received a positive SARS-CoV-2 RT-PCR result.
91 Participants self-collected swabs for SARS-CoV-2 RT-PCR testing and oral fluid for antibody testing and
92 provided symptom information on study days 0, 3, 5, 7, 10, 14, 21 and 28. OutSMART samples collected

93 between April 23, 2020, and February 22, 2022, contributed to this analysis. The SEARCH study enrolled
94 households with at least one child <5 years old to participate in surveillance for incident SARS-CoV-2
95 infection for up to 8 months. Participants provided weekly nasal swabs for PCR testing and symptoms
96 information and, upon PCR-confirmed SARS-CoV-2 infection, up to eight weekly oral fluid samples.
97 SEARCH specimens collected between December 16, 2020, and October 6, 2021, contributed to this
98 analysis. More detailed information about the study designs has been published previously and is
99 provided in the **Supplement**. (11–14)

100 Oral fluid collection and multiplex SARS-CoV-2 antibody assays

101 Oral fluid (Oracol+, Malvern Medical Developments, UK) and nasal swabs for PCR testing were
102 participant-collected and mailed to the testing lab. Oral fluid collected 0 to 125 days after infection
103 onset was tested for SARS-CoV-2 receptor binding domain (RBD)- and Spike (S)-specific IgG, IgA and
104 secretory-component (SC)-containing Ig responses using magnetic bead-based multiplex immunoassays
105 optimized for oral fluid, as described previously.(15–17) Mucosal SC of polymeric Ig was detected using a
106 mouse monoclonal anti-SC antibody, followed by labeled anti-mouse antibody, hereafter referred to as
107 secretory IgA (SIgA) since IgA is the predominant secretory Ig in oral fluid.(18) Qualitative thresholds for
108 oral fluid anti-S and RBD IgG had been established previously.(16,19) Assay performance for detecting
109 anti-S-RBD IgG was 99.4% sensitivity (481/484 correct positives) and 99.3% specificity (995/1002 correct
110 negatives) using oral fluid from presumably naïve individuals (~1,000 samples), oral fluid collected >14
111 days after completing a COVID-19 vaccination series (~175 samples) and/or >14 days after symptoms
112 onset or after the first SARS-CoV-2 RT-PCR positive test (~325 samples).

113 Statistical analysis

114 *Time to viral clearance.* SARS-CoV-2 infection onset was defined as participant-reported COVID-19
115 symptom start date or the first PCR positive date, whichever occurred earlier. If asymptomatic, the first
116 PCR positive date was used. The date of viral clearance was defined as the median date between the last
117 SARS-CoV-2 RT-PCR positive and first negative nasal swab if less than 20 days apart.(12) If no first
118 negative nasal swab PCR test was available within 20 days after the last positive PCR test, the
119 individual's oral fluid samples were excluded from time to clearance analyses. Time to viral clearance in
120 days was calculated as the difference between infection onset and date of clearance as defined above.

121 *Symptom duration.* Similarly, symptom duration was defined as the difference in days between infection
122 onset and the median date between the last day on which any COVID-19 symptoms were reported and
123 the first asymptomatic day or, when available, the participant-reported date of symptoms resolution.

124 *COVID-19 symptoms.* Both studies assessed symptoms, however, symptom severity was only assessed in
125 OutSMART. COVID-19 symptoms considered here and assessed in both studies included fever and chills,
126 sore throat, loss of smell or taste, cough, congestion (nose, sinus pressure), body or muscle aches, chest
127 congestion or pain, shortness of breath or difficulty breathing and diarrhea. The number of reported
128 COVID-19 symptoms reported was calculated for each participant. In OutSMART the number of
129 symptoms of the study visit during which the most COVID-19 symptoms were reported was used. Most
130 participants reported the highest number of COVID-19 symptoms at enrollment through study day 3
131 (143/204 participants; 71%). SEARCH inquired weekly about onset of COVID-19 and other symptoms. To
132 capture COVID-19 symptoms reported within an equivalent time frame, COVID-19 symptoms reported

133 one week prior and up to two weeks after the first PCR positive test counted towards the number of
134 COVID-19 symptoms reported.

135 *Infecting SARS-CoV-2 variant.* If the infecting variant was unknown, the most prevalent variant (20)
136 circulating at the time of PCR-confirmed SARS-CoV-2 infection was imputed with wild type imputed for
137 infections occurring through February 2021; Alpha from March 2021 instead of April (20) to match the
138 sequencing-derived variant results available (SEARCH) through June 2021; Delta from July through
139 November 2021; and Omicron starting in December 2021 until study end. This approach resulted in
140 matching sequencing-based and imputed SARS-CoV-2 variant strains for all sequencing-confirmed SARS-
141 CoV-2 isolates (24/24 isolates in SEARCH and 7/7 confirmed Omicron isolates in OutSMART).

142 *Statistical models.* Cox proportional hazard models and Kaplan-Meier survival plots were used to assess
143 associations between temporal dynamics of oral fluid SARS-CoV-2 antibody levels and other factors with
144 time to viral clearance and COVID-19 symptom resolution. Asymptomatic individuals were assigned a
145 symptom duration of 0 days and included in analyses (coded in time to event analyses as 1 = resolution
146 of symptoms reached). Oral fluid anti-S antibody responses were classified into tertiles (low, moderate,
147 and high), allowing for stratified visualization with Kaplan-Meier survival plots and easier comparison
148 with other factors such as prior COVID-19 vaccine immunity. In another approach, participants were
149 classified into tertiles based on their median, rather than time-varying, anti-S response post infection
150 (low, moderate, high SIgA responder), while maintaining anti-S IgG as a time-varying covariate in the
151 model. A third approach used time-stratified analysis to test whether the direction and magnitude of
152 associations remained consistent over time.

153 In Cox proportional hazard models and in Kaplan-Meier survival analyses the event (viral clearance or
154 symptom resolution) was coded as 1. Therefore, in contrast to survival analyses where the event is
155 disease or death coded as 1, in the models presented here hazard ratios (HR)>1 indicate higher
156 likelihood of viral clearance or symptom resolution and shorter time to clearance or symptom resolution
157 in Kaplan-Meier analyses; HRs<0 indicate lower likelihood of and shorter time to clearance or symptom
158 resolution. Linear regression models with generalized estimating equations (GEE) were also used to
159 estimate the effect of anti-S and anti-RBD SIgA, IgA and IgG responses on time to clearance and
160 symptom duration.

161 Models were adjusted for COVID-19 vaccination status (received at least 1 COVID-19 vaccine dose versus
162 unvaccinated at time of infection), infecting variant, age group (<5, 5-17, >=18, >65 years), sex, race, and
163 ethnicity. GEE models were also adjusted for time since infection onset. All models included clustering
164 equations to account for non-independence of repeated oral fluid measurements within individual.
165 Collinearity between independent covariates was estimated by calculating variance inflation factors for
166 all models. Only models with variance inflation factors under 4 are presented here. Analyses were
167 performed in R version 4.2.1 using packages tidyverse, survival, survminer, forestploter, adjustedCurves,
168 ggpubr, and car.

169 **Results**

170 Oral fluid samples (n=1,256) from 257 adults and children with PCR-confirmed COVID-19 infection who
171 participated either in the OutSMART or SEARCH cohort studies were analyzed for anti-RBD and anti-S
172 secretory component-containing Ig (predominantly secretory IgA [SIgA]), IgA and IgG responses. Almost
173 all participants experienced mild or moderate COVID-19 disease; children were more often

174 asymptomatic, as described in more detail elsewhere.(11–13) Participant characteristics stratified by
175 study cohort and combined are shown in **Table 1**. The median time from infection onset to viral
176 clearance, as defined above, was 15 days (interquartile range [IQR] = [9.5; 21.5]) and median time to
177 resolution of COVID-19 symptoms was 18 days (IQR = [9.25; 37.0]).

178 *Factors associated with SARS-CoV-2 clearance and COVID-19 symptom resolution.* Higher anti-S IgA
179 level and COVID-19 vaccination status were associated with greater likelihood of viral clearance and
180 resolution of symptoms (**Figure 1**). Moderate compared to low anti-S IgA was associated with a 1.8-fold
181 greater likelihood of viral clearance (adjusted hazard ratio [aHR] with 95% confidence interval [CI] = 1.8
182 [1.2-2.5]; $p=0.002$) and 1.7-fold greater likelihood of COVID-19 symptoms resolution (aHR [95% CI] = 1.7
183 [1.2-2.3], $p=0.003$). High compared to low anti-S IgA was associated with a 2.2-fold and 2.1-fold greater
184 likelihood of viral clearance (aHR [95% CI] = 2.2 [1.5-3.1], $p<0.001$) and symptom resolution (aHR [95%
185 CI] = 2.1 [1.5-2.9], $p<0.001$), respectively. Prior immunity from COVID-19 vaccination was also associated
186 with greater likelihood of clearance (aHR [95% CI] = 2.5 [1.8-3.4], $p<0.001$) and resolution of symptoms
187 (aHR [95% CI] = 1.9 [1.3-2.7], $p<0.001$). In contrast, higher anti-S IgG was associated with reduced
188 likelihood of viral clearance and symptoms resolution (**Figure 1**).

189 In children under 5 years of age, higher anti-S IgA was also associated with increased likelihood of viral
190 clearance (aHR [95% CI] for each \log_{10} increase in anti-S IgA = 1.4 [1.0-1.9], $p<0.05$) and of symptoms
191 resolution (aHR [95% CI] for each \log_{10} increase in anti-S IgA = 1.4 [1.2-1.6] $p<0.001$). Higher anti-S IgG
192 in children was associated with lower likelihood of viral clearance (aHR [95% CI] for each \log_{10} increase in
193 anti-S IgG = 0.6 [0.4-0.9], $p<0.01$; **Tables S1 and S7**). These trends remained consistent and statistically
194 significant in independent analyses of both study cohorts (**Tables S2-S3**) and of unvaccinated adults
195 (**Table S8**). In the OutSMART cohort, age >65 years was a risk factor for prolonged PCR positivity (aHR
196 [95% CI] = 0.6 [0.3-0.9], $p<0.05$; **Table S3**); the SEARCh cohort did not enroll participants over 65 years.
197 In the SEARCh cohort, younger age (children 0-17 years old) was associated with greater likelihood of
198 viral clearance (aHR [95% CI] = 1.35 [1.02-1.80], $p<0.05$; **Table S4**). Adjusting for the infecting variant did
199 not affect the magnitude or direction of these associations significantly but showed that Delta and
200 Omicron infections were associated with significantly shorter time to viral clearance than wildtype
201 infections (**Table S5**).

202 *Differences in time to clearance and symptoms resolution.* In Kaplan-Meier survival estimates stratified
203 by anti-S IgA tertile, moderate oral fluid anti-S IgA compared to low IgA was associated with clearing
204 the virus 10 days earlier (95% CI: 7-14 days) and with becoming asymptomatic 9 days (95% CI: 6-14 days)
205 earlier. High compared to low anti-S IgA was associated with clearing the virus 14 days (95% CI: 10-18
206 days) earlier and with becoming asymptomatic 14 days (95%CI: 10-17 days) earlier (**Figure 2**). The
207 direction and effect size of these associations remained consistent over time as confirmed with time
208 since infection restricted subsets of oral fluid and using participants' median rather than time varying
209 IgA response post infection (see **Supplement Time-restricted models and Median IgA response post**
210 **infection**).

211 *Association of oral fluid anti-RBD Ig with time to clearance and COVID-19 symptoms duration.* Mucosal
212 SARS-CoV-2 RBD-specific IgA and IgG in children and adults were higher among the two-thirds of study
213 participants (67%) who cleared the virus within 18 days post infection onset compared to those who
214 tested PCR positive longer (**Figure S2**). Oral fluid SARS-CoV-2 IgG levels, which correlate with serum
215 SARS-CoV-2 IgG levels (16,17), were similar in individuals who cleared the virus in ≤ 18 days and >18 days

216 among adults. The number of children that did not clear the virus within 18 days ($n=4$) was too small for
217 representative comparison of the two groups (**Figure S2**). Adults who resolved symptoms within four
218 weeks had significantly higher anti-RBD SIgA and IgA, but not IgG, 15-30 days after infection onset than
219 individuals who remained symptomatic longer than four weeks ($p<0.0001$; **Figure S3**).

220 *Association between delayed seroconversion and viral clearance.* Even though higher anti-S IgG in oral
221 fluid was associated with longer time to viral clearance, shorter time to a first positive oral fluid anti-S
222 IgG result (shorter time to seroconversion) remained associated with faster viral clearance (**Table S6**), as
223 shown previously in a subset of the OutSMART cohort.(12) GEE models estimated a 0.8-day increase
224 (beta [SE] = 0.8 [0.2], $p<0.001$) in time to clearance for each one-day delay in time to anti-S IgG
225 seroconversion.

226 *Linear regression model to estimate associations between oral fluid anti-S and anti-RBD Ig and time to*
227 *SARS-CoV-2 clearance or COVID-19 symptoms duration.* Each \log_{10} unit increase in anti-S and anti-RBD
228 SIgA and IgA was associated with three to five days faster viral clearance and COVID-19 symptoms
229 resolution. Every \log_{10} increase of oral fluid anti-RBD (Sino Biological, China) SIgA was associated with
230 beta [SE] -2.7 days [1.3], $p<0.05$ faster viral clearance; while every \log_{10} increase in anti-S (Mt. Sinai) IgA
231 was associated with 3.4 days faster viral clearance (beta [SE]: -3.4 days [1.3]; $p<0.01$, **Table S9**). Similarly,
232 each \log_{10} increase in oral fluid anti-S-RBD was associated with 3.4 to 4.9 days earlier resolution of
233 COVID-19 symptoms (beta [SE]: -3.4 [1.6]; $p<0.05$ to -4.9 [1.9] days, $p<0.01$, **Table S10**). Higher anti-S IgG
234 was again associated with longer time to clearance and to becoming asymptomatic. Children cleared the
235 virus about one week earlier than adults (beta [SE] = -6.8 days (2.7); $p<0.01$) and recovered significantly
236 faster from COVID-19 symptoms than adults (beta [SE] = -16.5 (2.7); $p<0.001$), while among adults self-
237 reported Black race appeared associated with longer time to clearance and symptoms duration (**Table**
238 **S10**).

239 Lastly, we investigated whether the mucosal immune response to SARS-CoV-2 differed depending on
240 the maximum number of COVID-19 symptoms reported (0-3, 4-6, or >6 symptoms). Participants who
241 reported experiencing >6 compared to 4-6 and 0-3 COVID-19 symptoms had higher anti-RBD IgG 14-30
242 days after infection onset. This trend was consistent among children (Kruskal-Wallis $p<0.05$) and among
243 adults ($p<0.01$) but anti-RBD IgG <14 days post infection and anti-RBD SIgA or IgA did not appear
244 associated with the number of COVID-19 symptoms reported (**Figure S4**).

245 **Discussion**

246 Among children and adults, early and robust mucosal SARS-CoV-2 SIgA and IgA responses in oral fluid
247 were associated with faster viral clearance and earlier recovery from COVID-19 symptoms. Early anti-S
248 IgG seroconversion was associated with faster viral clearance, as shown before in the OutSMART cohort
249 (12), while higher anti-S IgG was associated with longer time to clearance and to resolution of COVID-19
250 symptoms. These findings are consistent with prior research showing positive correlations between
251 blood anti-S IgG and nAb titers in convalescence and COVID-19 disease severity and symptoms duration
252 (21–23), and between delayed nAb and anti-S IgG responses and severe outcomes in children and fatal
253 outcomes COVID-19 in adults.(23,24) Our group has also demonstrated that prolonged time to viral
254 clearance during the acute phase of SARS-CoV-2 infection is associated with long COVID.(25) We showed
255 that COVID-19 vaccine-induced immunity at the time of infection was associated with faster clearance
256 and earlier resolution of symptoms with equivalent effect size as moderate and high SIgA. Early, robust
257 anti-S SIgA responses in oral fluid may thus be a correlate for protection from prolonged viral

258 persistence and from prolonged duration of COVID-19 symptom with comparable magnitude as
259 conferred by intramuscular COVID-19 vaccination.

260 These findings are consistent with a model in which early and robust local mucosal anti-S SIgA and
261 timely IgG seroconversion contribute to early viral clearance, e.g., by blocking viral attachment to
262 mucosal cell surfaces (SARS-CoV-2 binding to ACE2) and thus preventing infection of target epithelial
263 cells and later spread to other sites of infection. In this model, individuals who cannot mount early and
264 robust local mucosal anti-S SIgA responses and/or who experience prolonged time to rise of anti-S IgG
265 are more likely to experience prolonged unmitigated infection, higher virion burden at sites of infection,
266 and/or systemic spread. These individuals would have a higher burden of viral antigen interacting with B
267 cells throughout lymphatic tissue and therefore would be more likely to eventually mount higher titers
268 of anti-SARS-CoV-2 IgG.

269 Limitations of this research included that the SEARCH and OutSMART study COVID-19 symptoms
270 assessments were not administered at the same time intervals relative to COVID-19 infection and that
271 symptom severity was only captured in one of the two cohorts, thus limiting the sample size to
272 investigate associations between oral fluid antibody responses and COVID-19 severity. Only the number
273 of SARS-CoV-2 symptoms, which were reported in both cohorts, and symptom duration but not
274 symptom severity in relation to oral mucosal antibody responses were investigated here.

275 We showed that unvaccinated adults who experienced COVID-19 symptoms for more than four weeks
276 had significantly lower levels of oral fluid anti-RBD SIgA and IgA than those who resolved symptoms
277 earlier. However, we could not assess the role of SIgA in the development of long COVID here. Post
278 COVID Conditions, including symptoms such as fatigue, post-exertional malaise, and brain fog that
279 persist beyond or start after the four-week COVID-19 symptom duration period, were ascertained in
280 only one of the study cohorts and were therefore excluded from this analysis.

281 Since in OutSMART PCR measurements were only available on select study days rather than weekly,
282 approximately 50 out of 300 potential participants with either missing or delayed first negative PCR tests
283 (≥ 20 days after the last PCR positive test) had to be excluded from time to event analyses. Similarly,
284 SEARCH study participants who experienced COVID-19 infection near the end of the study period were
285 excluded since date of first PCR negative nasal swab and of symptoms resolution were not ascertained
286 and thus time to clearance and symptoms duration could not be calculated. Others modeled the viral
287 shedding duration and the time to SIgA seroconversion in nasopharyngeal swabs based on the viral
288 dynamics observed in other studies.(7) Here we chose to only include participants for which oral fluid
289 antibody measurements were obtained and time to viral clearance (first SARS-CoV-2 PCR negative test)
290 and symptoms duration could be calculated.

291 Finally, this study used qualitative FDA-EUA-approved SARS-CoV-2 PCR assays to infer time to viral
292 clearance rather than SARS-CoV-2 virus culture, which was only available for a subset of PCR-positive
293 swabs and originated from different laboratories. Therefore, the time to viral clearance used in this
294 analysis represents the time from participant-reported symptoms onset or first PCR positive test to the
295 first SARS-CoV-2 PCR negative test and is likely longer than the SARS-CoV-2 transmission window during
296 which infectious virus is shed.

297 A Swedish study of COVID-19 vaccinated healthcare workers found that high post-vaccination SARS-CoV-
298 2 specific SIgA levels may protect from SARS-CoV-2 breakthrough infections and recent research showed

299 that the model-inferred duration of viral shedding duration was reduced when estimated nasal anti-S
300 SIgA seroconversion occurred earlier.(5,7) Taken together, these studies and our research indicate that
301 vaccine strategies that boost mucosal humoral immune responses, such as intranasal or inhaled SARS-
302 CoV-2 vaccines known to boost S-RBD-binding local SIgA, may help protect from breakthrough SARS-
303 CoV-2 infection, reduce the window for transmission, and reduce the duration and severity of COVID-19
304 symptoms following infection.(9,10,26) These findings underscore the importance of measures of
305 mucosal immunogenicity, particularly standardization and harmonization as large-scale mucosal
306 vaccination efforts such as Project NextGen proceed.

307 Future studies should investigate if mucosal anti-S SIgA could be a mechanistic (i.e., causal) or
308 nonmechanistic correlate (i.e., associated, but not the primary mechanistic cause) (27,28) for faster viral
309 clearance and resolution of COVID-19 symptoms. Mucosal secretory antibody responses are among
310 several immune functions that could contribute to effective clearance of SARS-CoV-2 in addition to
311 innate immune responses and other adaptive immune responses including antigen-specific killing of
312 infected cells by CD8⁺ T cells.(29) Our work indicates a role for SIgA in clearance of virus and resolution
313 of symptoms. Future work should focus on whether mucosal anti-S/RBD SIgA responses during acute
314 SARS-CoV-2 infection are associated with later development of Post COVID Conditions, which include
315 the persistence of COVID-19 symptoms, recurrence, or development of new symptoms four or more
316 weeks after an initial SARS-CoV-2 infection.(30)

317 **Funding**


318 Funding for this study was provided by the Johns Hopkins COVID-19 Research Response Program and
319 the FIA Foundation. N.P., K.K., and C.D.H. were supported by a gift from the GRACE Communications
320 Foundation. C.D.H., N.P., and B.D. were additionally supported by the National Institute of Allergy and
321 Infectious Diseases (NIAID) grants R21AI139784 and R43AI141265 and the National Institute of
322 Environmental Health Sciences (NIEHS) grant R01ES026973. C.D.H. was also supported by NIAID grant
323 R01AI130066 and R01ES026973. C.D.H. was also supported by NIH. grant U24OD023382. YM received
324 support for this work from the Henry M. Jackson Foundation for the Advancement of Military Medicine
325 (contract number 1007957) and the Sherrilyn and Ken Fisher Center for Environmental Infectious
326 Diseases Discovery Program. AA is supported by the National Institutes of Health (grant number
327 K08AI143391). This work was supported by the Sherrilyn and Ken Fisher Center for Environmental
328 Infectious Diseases Discovery Program and the Johns Hopkins University School of Medicine COVID-19
329 Research Fund. Y.C.M. received salary support from the National Institutes of Health (grant numbers
330 U54EB007958-12, U5411090366, U54HL143541-02S2, UM1AI068613). The SEARCH study was funded by
331 the Centers for Disease Control and Prevention, grant number 75D30120C08737.

332 **Table 1.** Participant characteristics by study cohort

Participant characteristic	OutSMART	SEARCH	Combined
Participants, n	208	49	257
Prior Immunity			
Vaccinated against COVID-19, n (%)	38 (18%)	4 (8%)	42 (16%)
Not COVID-19 vaccinated, n (%)	170 (82%)	45 (92%)	215 (84%)
Sex			
Female	124 (60%)	23 (47%)	147 (57%)
Male	84 (40%)	26 (53%)	110 (43%)
Age Group			
0-4 years, n (%)	3 (1%)	19 (39%)	22 (9%)
5-17 years, n (%)	7 (3%)	11 (22%)	18 (7%)
>=18 years, n (%)	167 (80%)	19 (39%)	186 (72%)
>65 years, n (%)	31 (15%)	0 (0%)	31 (12%)
Race / Ethnicity			
White, non-Hispanic	94 (45%)	35 (71%)	129 (50%)
Black, non-Hispanic	74 (36%)	1 (2%)	75 (29%)
Multiracial, non-Hispanic	12 (6%)	9 (18%)	21 (8%)
Hispanic	28 (13%)	1 (2%)	29 (11%)
SARS-CoV-2 Variant			
Wildtype	136 (65%)	18 (37%)	154 (60%)
Alpha	41 (20%)	18 (37%)	59 (23%)
Delta	21 (10%)	13 (26%)	34 (13%)
Omicron	10 (5%)	0 (0%)	10 (4%)
Days to viral clearance, median (IQR)	15.5 (12 - 23.5)	10.5 (7.5-16.5)	15 (9.5 - 21.5)
Days to COVID-19 symptoms resolution, median (IQR)	25 (13.5 - 25)	5 (0 - 10)	18 (9.25-37)
Days to first oral fluid collection after symptoms onset or first SARS-CoV-2 positive PCR if asymptomatic, median (IQR)	9 (5 - 16.5)	7 (5 - 9)	8 (5 - 13)
Days to oral fluid collection, median (IQR)*	18 (11 - 34)	33.5 (15 - 55)	22 (12 - 43)
Oral fluid samples, n	838	418	1256


333 **Note:** IQR = interquartile range (25%ile – 75%ile). *Oral fluid was collected weekly (SEARCH) after SARS-
334 CoV-2 PCR positive test or on study days 0, 3, 5, 7, 10, 14, 21, 28 (OutSMART).

335 **A. SARS-CoV-2 clearance.**




336

337 **B. COVID-19 symptom resolution.**



338

339 **Figure 1.** Cox proportional hazard model to assess factors associated with **A.** SARS-CoV-2 clearance (first
340 SARS-CoV-2 PCR negative test) and **B.** COVID-19 symptom resolution. **Note:** aHR = hazard ratio
341 estimated from Cox proportional hazard model adjusted for all covariates presented in the table and
342 clustered at the individual level. CI = Confidence interval. SC = Secretory component. In time to event
343 analyses 1 = time individual **(A)** clears the SARS-CoV-2 virus (tests SARS-CoV-2 PCR negative), or **(B)**
344 reports being asymptomatic; 0 = individual continues to **(A)** test SARS-CoV-2 PCR positive, or **(B)** report
345 COVID-19 symptoms. HRs > 1.0 indicate higher likelihood and HRs < 1.0 indicate lower likelihood of **(A)**
346 SARS-CoV-2 clearance, or **(B)** resolution of COVID-19 symptoms.



347

348 **Figure 2.** Kaplan-Meier survival curves stratified by oral fluid anti-spike SIgA response post COVID-19
349 symptoms onset (low; moderate and high SIgA tertile). **A.** Probability of testing SARS-CoV-2 PCR positive
350 over time in days. **B.** Probability of persisting COVID-19 symptoms over time in days.

351 **References**

- 352 1. Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Severity and Outcomes of SARS-CoV-2 Reinfection
353 Compared with Primary Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res*
354 *Public Health*. 2023 Feb 1;20(4).
- 355 2. Suleyman G, Fadel R, Patel K, Shadid AM, Stuart HBC, Kattula M, et al. Outcomes associated with
356 SARS-CoV-2 reinfection in individuals with natural and hybrid immunity. *J Infect Public Health*
357 [Internet]. 2023 Aug 1 [cited 2024 Jan 11];16(8):1262–8. Available from:
358 <https://pubmed.ncbi.nlm.nih.gov/37302273/>
- 359 3. Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained - A
360 Correlate of Protection for Vaccines. *N Engl J Med*. 2022 Dec 15;387(24):2203–6.
- 361 4. Becerra X, Jha A. Project NextGen — Defeating SARS-CoV-2 and Preparing for the Next Pandemic.
362 *New England Journal of Medicine* [Internet]. 2023 Aug 31 [cited 2024 Feb 18];389(9):773–5.
363 Available from: <https://www.nejm.org/doi/full/10.1056/NEJMp2307867>
- 364 5. Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, et al. Anti-Spike
365 Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. *N Engl J Med* [Internet]. 2022 Oct
366 6 [cited 2023 Apr 4];387(14):1333–6. Available from: [/pmc/articles/PMC9511632/](https://pubmed.ncbi.nlm.nih.gov/37302273/)
- 367 6. Fröberg J, Gillard J, Philipsen R, Lanke K, Rust J, van Tuijl D, et al. SARS-CoV-2 mucosal antibody
368 development and persistence and their relation to viral load and COVID-19 symptoms. *Nat*
369 *Commun* [Internet]. 2021 Dec 1 [cited 2023 Sep 5];12(1). Available from:
370 [/pmc/articles/PMC8460778/](https://pubmed.ncbi.nlm.nih.gov/37302273/)
- 371 7. Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, et al. Infectious virus shedding
372 duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
373 *Proceedings of the National Academy of Sciences* [Internet]. 2023 Dec 22 [cited 2024 Jan
374 2];120(52):e2314808120. Available from:
375 <https://www.pnas.org/doi/abs/10.1073/pnas.2314808120>
- 376 8. Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Vol. 21, *Nature*
377 *Reviews Microbiology*. Nature Publishing Group; 2023. p. 147–61.
- 378 9. McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann NP, et al. Mucosal boosting
379 enhances vaccine protection against SARS-CoV-2 in macaques. *Nature* 2023 [Internet]. 2023 Dec
380 14 [cited 2024 Jan 11];1–3. Available from: [https://www.nature.com/articles/s41586-023-06951-](https://www.nature.com/articles/s41586-023-06951-3)
381 [3](https://www.nature.com/articles/s41586-023-06951-3)
- 382 10. Knisely JM, Buyon LE, Mandt R, Farkas R, Balasingam S, Bok K, et al. Mucosal vaccines for SARS-
383 CoV-2: scientific gaps and opportunities-workshop report. *NPJ Vaccines* [Internet]. 2023 Dec 1
384 [cited 2024 Jan 11];8(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/37045860/>
- 385 11. Blair PW, Brown DM, Jang M, Antar AAR, Keruly JC, Bachu VS, et al. The Clinical Course of COVID-
386 19 in the Outpatient Setting: A Prospective Cohort Study. *Open Forum Infect Dis*. 2021 Feb 1;8(2).
- 387 12. Antar AAR, Yu T, Pisanic N, Azamfirei R, Tornheim JA, Brown DM, et al. Delayed Rise of Oral Fluid
388 Antibodies, Elevated BMI, and Absence of Early Fever Correlate with Longer Time to SARS-CoV-2

- 389 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. *Open Forum Infect*
390 *Dis.* 2021 Jun 1;8(6).
- 391 13. Karron RA, Hetrich MK, Na Y Bin, Knoll MD, Schappell E, Meece J, et al. Assessment of Clinical and
392 Virological Characteristics of SARS-CoV-2 Infection Among Children Aged 0 to 4 Years and Their
393 Household Members. *JAMA Netw Open* [Internet]. 2022 Aug 1 [cited 2023 Apr 4];5(8):e2227348–
394 e2227348. Available from:
395 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2795801>
- 396 14. Dawood FS, Couture A, Zhang X, Stockwell MS, Porucznik CA, Stanford JB, et al. Severe Acute
397 Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Responses After Community
398 Infections in Children and Adults. *Open Forum Infect Dis* [Internet]. 2023 May 3 [cited 2023 Sep
399 12];10(5). Available from: <https://dx.doi.org/10.1093/ofid/ofad168>
- 400 15. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 serology at
401 population scale: SARS-CoV-2-specific antibody responses in saliva. *J Clin Microbiol.* 2021 Jan
402 1;59(1).
- 403 16. Pisanic N, Antar AAR, Kruczynski KL, Gregory Rivera M, Dhakal S, Spicer K, et al. Methodological
404 approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation
405 with serologic and neutralizing antibody responses. *J Immunol Methods.* 2023 Mar 1;514.
- 406 17. Heaney CD, Pisanic N, Randad PR, Kruczynski K, Howard T, Zhu X, et al. Comparative performance
407 of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and
408 neutralization titers. *Journal of Clinical Virology.* 2021 Dec 1;145.
- 409 18. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. *J Oral Microbiol.*
410 2013;5(2013):1–24.
- 411 19. Gigot C, Pisanic N, Kruczynski K, Gregory Rivera M, Spicer K, Kurowski KM, et al. SARS-CoV-2
412 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community
413 Residents, North Carolina, 2021 to 2022. *mSphere.* 2023 Feb 21;8(1).
- 414 20. Quintero AM, Eisner M, Sayegh R, Wright T, Ramilo O, Leber AL, et al. Differences in SARS-CoV-2
415 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant -
416 Volume 28, Number 11—November 2022 - *Emerging Infectious Diseases journal - CDC.* *Emerg*
417 *Infect Dis* [Internet]. 2022 Nov 1 [cited 2023 Nov 7];28(11):2270–80. Available from:
418 https://wwwnc.cdc.gov/eid/article/28/11/22-0577_article
- 419 21. Sejdic A, Frische A, Jørgensen CS, Rasmussen LD, Trebbien R, Dungu A, et al. High titers of
420 neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with
421 increased severity in COVID-19 hospitalized patients. *Virology* [Internet]. 2023 Dec 1 [cited 2023
422 Nov 8];20(1):1–12. Available from:
423 <https://virologyj.biomedcentral.com/articles/10.1186/s12985-023-01974-8>
- 424 22. Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-specific
425 neutralizing antibody responses in COVID-19. *Signal Transduction and Targeted Therapy* 2020 5:1
426 [Internet]. 2020 Sep 2 [cited 2023 Nov 8];5(1):1–6. Available from:
427 <https://www.nature.com/articles/s41392-020-00301-9>

- 428 23. Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, et al. Delayed production of neutralizing
429 antibodies correlates with fatal COVID-19. *Nat Med* [Internet]. 2021 Jul 1 [cited 2023 Nov
430 8];27(7):1178–86. Available from: <https://pubmed.ncbi.nlm.nih.gov/33953384/>
- 431 24. Sananez I, Raiden SC, Algieri SC, Uranga M, Grisolia NA, Filippo D, et al. A poor and delayed anti-
432 SARS-CoV2 IgG response is associated to severe COVID-19 in children. *EBioMedicine* [Internet].
433 2021 Oct 1 [cited 2023 Nov 8];72:103615. Available from: [/pmc/articles/PMC8502533/](https://pubmed.ncbi.nlm.nih.gov/3502533/)
- 434 25. Antar AAR, Yu T, Demko ZO, Hu C, Tornheim JA, Blair PW, et al. Long COVID brain fog and muscle
435 pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory
436 tract during acute infection. *Front Immunol*. 2023 Apr 28;14:1147549.
- 437 26. Hempel H, Mantis N, Heaney CD, Pinto LA. The SeroNet Clinical and Translational Serology Task
438 Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices
439 workshop. *Hum Vaccin Immunother* [Internet]. 2023 Aug 1 [cited 2023 Sep 12];19(2). Available
440 from: <https://www.tandfonline.com/doi/full/10.1080/21645515.2023.2253598>
- 441 27. Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained - A
442 Correlate of Protection for Vaccines. *N Engl J Med* [Internet]. 2022 Dec 15 [cited 2023 Apr
443 4];387(24):2203–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/36507702/>
- 444 28. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. *Clin
445 Infect Dis* [Internet]. 2012 Jun 1 [cited 2024 Jan 2];54(11):1615–7. Available from:
446 <https://pubmed.ncbi.nlm.nih.gov/22437237/>
- 447 29. Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and vaccination in
448 the respiratory tract. *Immunity* [Internet]. 2022 May 10 [cited 2024 Jan 2];55(5):749–80.
449 Available from: <http://www.cell.com/article/S1074761322001844/fulltext>
- 450 30. Post-COVID Conditions: Information for Healthcare Providers [Internet]. [cited 2024 Jan 11].
451 Available from: [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-
452 conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html)
- 453